Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
TOKYO and CAMBRIDGE, Mass., Mar 4, 2025 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia).In October 2024…
Read More
0
